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Elaboration of tetra-orthogonally-substituted
aromatic scaﬀolds towards novel EGFR-kinase
inhibitors†
Adam J. Close,a Rhiannon N. Jones,a Cory A. Ocasio,a Paul Kemmitt,b S. Mark Roec
and John Spencer*a
Nitration of three regioisomers of bromo-ﬂuorobenzaldehyde proceeds regioselectively, notably with
H2SO4/HNO3 at 0 °C. The thereby synthesized tetrasubstituted aromatics, endowed with orthogonal sub-
stituents, can be elaborated via Pd-catalysed coupling, reduction and reductive amination reactions. As a
test-case, these compounds were converted into EGFR inhibitors related to Geﬁtinib, whose activity was
rationalised by docking studies.
Introduction
Tetrasubstituted aromatics are commonplace in drug discovery
yet regioselective routes towards these compounds, which often
contain orthogonal groups, are rather scarce.1 Kinase inhibitors
are a rapidly growing class of anticancer agents and many of
these comprise such tetrasubstituted scaﬀolds, often built
around an adenine-like quinazoline scaﬀold, a solubilising
group (e.g. ethers, morpholine or piperazine groups) and a tri or
tetra-substituted aromatic, hydrophobic group that imparts
selectivity towards particular classes of kinase (Fig. 1).2–5
To underline their importance, the synthesis of the recently
approved irreversible EGFR (epidermal growth factor receptor
tyrosine kinase family; HER1) inhibitor Osimertinib, starts
with a somewhat simple, yet non-trivial, tetrasubstituted pre-
cursor, which comprises four orthogonal substituents (Fig. 2).6
We have recently reported procedures for forming poyl-
substituted aromatics, mainly based on a MIDA boronate-
substituted aryl scaﬀold.7,8 Our aim was to synthesise ana-
logues of the type I and II (Fig. 3) as useful 1,2,3,4- and 1,2,4,5-
substituted building blocks.
Here, we report our investigation of the synthesis of related
scaﬀolds, which do not include a MIDAboronate aryl scaﬀold
but are substituted with bromo, fluoro and formyl substitu-
Fig. 1 Kinase inhibitors, highlighting the aromatic hydrophobic (blue),
the adenine mimic (red) and solubilising group (green).
Fig. 2 Demonstration of a tetrasubstituted aromatic used as a building
block in anticancer molecules.
†Electronic supplementary information (ESI) available. CCDC 1485121–1485123.
For ESI and crystallographic data in CIF or other electronic format see DOI:
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ents. We show that these orthogonal groups can be modified
in order to furnish useful drug-like fragments as well as tetra-
substituted units that can be incorporated into potential
kinase inhibitors.
Results and discussion
Brominations on trisubstituted aromatics are an eﬀective
means for synthesising tetrasubstitued aromatic units contain-
ing orthogonal (e.g. MIDA and bromide) groups. These elec-
trophilic substitutions work with excellent regioselectivity
when complementary directing groups are combined in the
trisubstituted precursor. We now disclose our results on
the related nitrations of trisubstituted (non-MIDA) aromatics
and resulting functional group conversions thereafter
aﬀording novel tetrasubstituted frameworks. In order to main-
tain our ethos of elaborating orthogonally substituted aro-
matics we refrained from attempting the bromination of
bromoaromatics.
We attempted the nitration of three regioiomers of bromo-
fluorobenzaldehyde (Table 1). Compounds 2a and 2b have
been previously synthesised, described in patents, via
nitration, using varying amounts of nitric acid in sulphuric
acid.9,10 We required a generic, high yielding method for these
three compounds and thus looked for alternative methods.
Compound 1a was used to probe diﬀerent nitration conditions
due to the complementarity of the directing groups, which
would be expected to give one regioisomer. Initial attempts
included the use of potassium nitrate in sulphuric acid11 and
Mn(acac)3 in DCM with nitric acid,
12 neither of which gave
good results, as analysed by crude 1H-NMR spectra.
We were pleased that the NO2BF4 method showed compar-
able yields for the synthesis of 2a (entry 1, Table 1) to that of the
nitric acid methods, adopted from the patents. For the synthesis
of 2b and 2c, yields were slightly lower. In general a nitric/
sulphuric acid mixture gave the best results and NO2BF4 proved
to be ineﬀective in the attempted nitration of 1b and 1c.13
The regiochemistry of the products 2a–2c was confirmed by
1H and 13C NMR spectroscopy as well as by single crystal X-ray
crystallography (Fig. 4).
Next, we sought a general method for reducing the nitro
compounds 2 and we found that iron in acetic acid was an
eﬀective means for forming the anilines 3. Compound 3a
has been synthesised previously using 10% platinum on
carbon although we found it less eﬀective than an alternative
iron-mediated method (Scheme 1).14
Unfortunately, a whole range of methods proved ineﬀective
in the attempted reduction of the regioisomer 2a (Scheme 2).
Fig. 3 Tetrasubstituted aromatic building blocks.
Table 1 Nitration of bromo-ﬂuorobenzaldehydes
Entry Starting material Product Yield (%)
1 88a,c
84b,d
94b, f
2 61b,e
74b, f
3 30b,e
27b, f
aNO2BF4 −20 °C – r.t., 16 h. bH2SO4/HNO3 0 °C – r.t., 16 h. c 12 mmol
scale. d 25 mmol scale. e 30 mmol scale. f 99 mmol scale.
Fig. 4 ORTEP diagrams showing crystal structures of 2b (left, CCDC
1485121), 2a (middle, CCDC 1485122) and 2c (right, CCDC 1485123). All
are shown in Table 1. Red = oxygen blue = nitrogen, brown = bromine,
green = ﬂuorine, grey = carbon and white = hydrogen.
Scheme 1 Iron-mediated reductions of compounds 2b and 2c.
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Nevertheless, by changing the reaction sequence (vide infra,
Scheme 5) this issue can be circumvented and elaborated tetra-
substituted units can be synthesised.
Alkyne groups are present in a number of kinase inhibitors
such as Erlotinib (Fig. 1) and can also be used in e.g. indole
forming reactions.15–17 We carried out Sonogashira couplings
on 2a, 3a and 3b and obtained the silyl-protected alkynyl-
benzenes 4 in moderate to good yields (Scheme 3).
To show a broader synthetic scope, ethynyl MIDA phenyl-
boronate derivatives were also included, although a slightly
modified protocol was employed, since an excess of aryl halide
was required as the halide could be removed with ease on
silica gel (Scheme 4).18
Scheme 2 Nitro group reductions attempted on compound 2a.
Scheme 3 Compounds synthesised via Sonogashira cross-coupling
reactions of trimethylsilylacetylene. aReaction performed at rt for 1 hour.
Scheme 4 Compounds synthesised via Sonogashira cross-coupling
reactions of ethynyl MIDAphenylboronates.
Table 2 Compounds formed by reductive aminations
Entry Starting material Product Yield (%)
1e 2b 47a
77b
2 f 3a 83a
91c
3 f 3a 97a
4e 3b 82a
95d
5e 3b 95a
6e 4c 28a
7e 4c 63a
a 0.5 mmol scale. b 8 mmol scale. c 3 mmol scale. d 6.3 mmol scale.
e 2 eq. of STAB. f 2.5 eq. of STAB.
Scheme 5 Zinc-mediated nitro reductions of compound 5a.
Scheme 6 Clauson-Kaas pyrrole synthesis under microwave conditions
on compound 5d.
Paper Organic & Biomolecular Chemistry
8248 | Org. Biomol. Chem., 2016, 14, 8246–8252 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
4/
09
/2
01
6 
22
:1
1:
12
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
A STAB (sodium triacetoxyborohydride)-mediated reductive
amination of the formyl group in a selection of the com-
pounds 2–4 was performed in order to form benzyl-substituted
piperazine or morpholine derivatives (Table 2). Yields in
general were good and these reactions proceeded selectively in
the presence of an aniline substituent e.g. entries 2–5
(Table 2). Deprotected analogues of e.g. 5d, may prove to be
useful synthons for further derivatisation or as novel Ro3 (rule
of three) fragments in drug discovery projects.19,20
Nitro reduction of 5a was achieved, in moderate yield, using
zinc in the presence of ammonium chloride, in order to main-
tain the acid-sensitive Boc protecting group. This represents
an indirect route for obtaining the product 3c since it is a
derivative of the recalcitrant nitro precursor 2a.
Having synthesized a range of tetrasubstituted anilines we
wished to perform further modification of the aniline moiety.
Firstly a Clauson-Kaas pyrrole synthesis was performed on the
aniline 5d, which led to the pyrrole 6a (Scheme 6). Gratifyingly,
the Boc-protecting group withstood the harsh microwave and
acidic conditions.
As a proof of principle, based on structural similarity to the
EGFR inhibitor Gefitinib and with the emergence of tetra-
substituted scaﬀolds leading to the development of anticancer
therapeutics (e.g. Osimertinib), we rationalised that com-
pounds 7–9 are likely to target the receptor tyrosine kinase,
EGFR. In order to assess the biological activity of our panel of
tetra-substituted small-molecules, we carried out a dual-pass
biological evaluation including in vitro and cellular-based
assays. Compound potency against EGFR (wild-type, Exon 20)
was established using a homogeneous time-resolved fluo-
rescence (HTRF) kinase assay, which measures the extent of
internal tyrosine phosphorylations. The hERG-CHO cell line
over-expresses the human Ether-à-go-go Related Gene (hERG),
which is a gene (KCNH2) that encodes a K+ channel (Kv11.1)
and is a red light toxicity alert in many drug discovery pro-
grammes (Table 3).
As a cautionary note, we did not embark on a drug discov-
ery programme; for example, the biological evaluation (vide
infra) was performed a long time after the synthesis of the
compounds, preventing for example, any new syntheses and
fine tuning of the products to address pharmacokinetics or
oﬀ-target issues or to further investigate SAR (structure activity
relationships).
Commercially available 4-chloro-6,7-dimethoxyquinazoline
was reacted with anilines 3c, 5b, and 5d to aﬀord 7a–7c in
moderate to good yields (Scheme 7). We found that the use of
sodium bis(trimethylsilyl)amide (NaHDMS) gave the product
without deprotection of the Boc piperazine, unlike commonly
used acid catalysed protocols.21 Boc-deprotection was achieved
by the addition of hydrochloric acid in 1,4-dioxane (Scheme 8)
and purification was achieved by simply using solid phase
extraction (strong cation exchange, SCX, column), giving
8a–8c.
These newly synthesised secondary amines could be easily
functionalised to sulphonamides or amides in high yields par-
ticularity in the case of 9b and 9c (Scheme 9).
Compounds 7–9 were tested for inhibition of wild-type
EGFR (Table 3). These results show that all of the com-
pounds containing a BOC protecting groups were inactive
except for 7c, which had a high IC50 (21.5 µM). None of the
compounds with regiochemistry resulting from the 2a series
Scheme 7 Linking of the quinazoline unit.
Scheme 8 Boc cleavage.
Scheme 9 Functionalization of the piperazine unit.
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Table 3 Biological studies of the synthesized molecules
Compounds synthesised from 2b Compounds synthesised from 2c Compounds synthesised from 2a
Compound
EGFR
IC50
a
Mean hERG
inhibitionb (%)
Dock
scorec Compound
EGFR
IC50
a
Mean hERG
inhibitionb (%)
Dock
scorec Compound
EGFR
IC50
a
Mean hERG
inhibitionb (%)
Dock
scorec
0.0184 61.1 −7.849 0.935 44.5 −8.895 >21.3 33.7 −5.986
0.377 96.5 21.5 21.5 27.1 46.4
0.546 55.6 >30 43.9
>30 19.5
a EGFR Ex20 WT HTRF CR GMean IC50 (µM).
b hERG Hu CHO IF EPhs SS GD mean, at 10 μM. cUsing Schrodinger Glide.
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i.e. 8a, 7a and 9a showed any appreciable activity. The most
active compound was 8b (entry 8) which gave an IC50 of 18.4
nM. All of the compounds in the 2b series gave good results
i.e. all IC50’s were less than 1 µM, with the exception of the
BOC protected compound 7b, which showed no activity.
Unfortunately the percentage hERG inhibition increased as
the activity of the compounds improved, as exemplified by 8b
(Table 3). There are ways in which to design out hERG inhi-
bitions e.g. by reducing lipophilicity, reducing the pKa of the
nitrogen atoms, increasing steric hindrance around the nitro-
gen atoms or decreasing the number of hydrogen bond accep-
tors, but, as mentioned above, this was not addressed.22
The biological data suggest that the solubilising group pipera-
zine ortho to the aniline moiety (linking to the quinazoline unit)
gave compounds of higher activity i.e. compounds in the 2b and
2c series. However, the series where the aniline and the piper-
azine groups are mutually meta, i.e. the 2a series, leads to a loss
of activity. To look in to the relationship between the meta and
ortho compounds we modelled the binding mode of the com-
pounds 8a–8c and produced docking poses (Table 3/Fig. 5).
To explore the binding mode of 8a–c in EGFR we performed
docking studies using the structure of the Gefitinib-EGFR
complex.23 We found that 8c was able to bind in a way similar
to Gefitinib forming archetypal hydrogen bonds between the
backbone N–H of Met793 and a structural water from the
nitrogen atoms of the quinazoline core (Fig. 5). An additional
hydrogen bond was formed from the protonated piperazine
and the carbonyl of Asp855. The halogenated phenyl group
was accommodated in the hydrophobic pocket however,
halogen substitution in 8c was not aligned so as to form the
halogen bonding exhibited in Gefitinib between the Cl⋯CvO
of Leu788.
Compound 8b, with halogen substitution meta- and para-
to the aniline group, was docked similarly with the quinazo-
line core and phenyl ring slightly shifting to form Br⋯H–N
(Asp855) and Br⋯OvC (Glu762) halogen bonds. The key inter-
action between Met793 and the quinazoline nitrogen was
formed but the bond with the structural water was not con-
served. An additional interaction between Arg841 and the pro-
tonated piperazine was formed.
Fig. 5 Docked 8a–c and comparison to Geﬁtinib, using Schrodinger Glide. (A) Docking poses of 8a–c. (B) Comparison of docked 8a–c with cocrys-
talized Geﬁtinib. (C) Cocrystal structure of geﬁtinib in EGFR (PDB code: 2ITY).
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Compound 8a, with the piperazine meta- to the aniline
cannot be docked in a mode similar to gefitinib and forces an
alternative binding mode whereby the methoxy-groups of the
quinazoline are forced into the hydrophobic pocket forming
hydrogen bonds between the oxygen of the MeO– and the H–N
of Lys745. This suggests, and is in agreement, that 8a will be
inactive or show a much lower potency towards EGFR.
Conclusions
A library of tetrasubstituted aromatics has been synthesized
starting with robust nitration chemistry. The library has been
elaborated into a series of useful potential intermediates for
drug discovery and final drug-like entities as exemplified by
the formation of a range of EGFR inhibitors that display low
nM inhibition.
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